SG Americas Securities LLC Has $147,000 Stock Position in OmniAb, Inc. (NASDAQ:OABI)

SG Americas Securities LLC increased its holdings in OmniAb, Inc. (NASDAQ:OABI) by 105.6% in the 3rd quarter, Holdings Channel reports. The fund owned 34,858 shares of the company’s stock after purchasing an additional 17,901 shares during the period. SG Americas Securities LLC’s holdings in OmniAb were worth $147,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of OABI. The Manufacturers Life Insurance Company purchased a new position in OmniAb during the second quarter valued at approximately $147,000. Squarepoint Ops LLC acquired a new stake in shares of OmniAb during the 2nd quarter valued at $449,000. Sei Investments Co. grew its holdings in shares of OmniAb by 11.0% during the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock valued at $109,000 after acquiring an additional 2,888 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of OmniAb by 6.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock valued at $11,296,000 after acquiring an additional 194,835 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in shares of OmniAb by 52.7% in the second quarter. American Century Companies Inc. now owns 110,036 shares of the company’s stock worth $413,000 after acquiring an additional 37,963 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Price Performance

Shares of NASDAQ:OABI opened at $3.75 on Friday. The stock has a market capitalization of $441.06 million, a P/E ratio of -5.86 and a beta of -0.13. The business has a 50-day moving average of $4.17 and a two-hundred day moving average of $4.33. OmniAb, Inc. has a fifty-two week low of $3.56 and a fifty-two week high of $6.72.

OmniAb (NASDAQ:OABI) last posted its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. OmniAb had a negative return on equity of 20.21% and a negative net margin of 287.29%. The firm had revenue of $7.61 million during the quarter, compared to analyst estimates of $6.52 million. During the same period in the previous year, the company earned ($0.15) EPS. As a group, research analysts expect that OmniAb, Inc. will post -0.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

OABI has been the subject of a number of recent research reports. Benchmark reaffirmed a “buy” rating and set a $8.00 price target on shares of OmniAb in a research note on Monday, August 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of OmniAb in a research report on Friday, August 16th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research report on Monday, August 12th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.